Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer

被引:22
|
作者
Okamura, Masako [2 ]
Akizuki, Nobuya [1 ]
Nakano, Tomohito [2 ]
Shimizu, Ken [2 ]
Ito, Tatsuhiko [1 ]
Akechi, Tatsuo [3 ]
Uchitomi, Yosuke [1 ]
机构
[1] Natl Canc Ctr Hosp E, Psychooncol Div, Res Ctr Innovat Oncol, Kashiwa, Chiba 2778577, Japan
[2] Natl Canc Ctr, Div Psychiat, Chuo Ku, Tokyo 1040045, Japan
[3] Nagoya City Univ, Sch Med, Dept Psychiat, Mizuho Ku, Nagoya, Aichi 4678601, Japan
关键词
algorithm; major depressive disorder; advanced cancer; antidepressant; clinical experience;
D O I
10.1002/pon.1213
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The objective of this study was to describe the applicability and the dropout of the pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer. Psychiatrists treated major depressive disorder in advanced cancer patients on the basis of the algorithm. For discussing the problems related to the algorithm, we reviewed the reasons for the non-application of the algorithm and the reasons for dropout of patients within a week of initiation of treatment. The algorithm was applied in 54 of 59 cases (applicability rate, 92%). The reasons for the non-application of the algorithm were as follows: the need to add a benzodiazepine to an antidepressant in 4 cases and the need to choose alprazolam despite the depression being moderate in severity, in order to obtain a rapid onset action and reduce anxiety in a patient with short prognosis. Nineteen of the 55 patients dropped out within a week of initiation of treatment based on the algorithm. Delirium was the most frequent reason for dropout. The applicability rate was high, but several problems were identified, including those related to the combination of antidepressants and benzodiazepines, pharmacological treatment of depression in patients with short prognosis, and delirium due to antidepressants. Copyright (C) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:154 / 160
页数:7
相关论文
共 50 条
  • [1] Clinical experience of the pharmacological treatment algorithm for major depression in advanced cancer patients: preliminary study
    Akizuki, N
    Okamura, H
    Akechi, T
    Nakano, T
    Yoshikawa, E
    Nakanishi, T
    Uchitomi, Y
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2002, 6 (02) : 83 - 89
  • [2] Pharmacological treatment for insomnia in patients with major depressive disorder
    Brietzke, Elisa
    Vazquez, Gustavo H.
    Kang, Melody J. Y.
    Soares, Claudio N.
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (11) : 1341 - 1349
  • [3] Program of algorithm for pharmacological treatment of major depressive disorder in China: Benefits or not?
    Zhu, Yuncheng
    Wang, Fang
    Wang, Fan
    Liu, Hongmei
    Guo, Xiaoyun
    Wang, Zuowei
    He, Ruoqiao
    Wu, Xiaohui
    Cao, Lan
    Wu, Zhiguo
    Peng, Daihui
    Fang, Yiru
    HELIYON, 2023, 9 (11)
  • [4] Suicidal ideation in advanced cancer patients without major depressive disorder
    Tang, Lili
    He, Yi
    Pang, Ying
    Su, Zhongge
    Zhou, Yuhe
    Wang, Yu
    Lu, Yongkui
    Jiang, Yu
    Han, Xinkun
    Song, Lihua
    Wang, Liping
    Li, Zimeng
    Lv, Xiaojun
    Wang, Yan
    Yao, Juntao
    Liu, Xiaohong
    Zhou, Xiaoyi
    He, Shuangzhi
    Zhang, Yening
    Song, Lili
    Li, Jinjiang
    Wang, Bingmei
    PSYCHO-ONCOLOGY, 2022, 31 (11) : 1941 - 1950
  • [5] Algorithm for the treatment of major depression in patients with advanced cancer
    Nakano, T
    Kugaya, A
    Akechi, T
    Mikami, I
    Okuyama, T
    Okamura, H
    Uchitomi, Y
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 1999, 53 : S61 - S65
  • [6] Use of an Analog Scale in the Treatment of Patients With Major Depressive Disorder to Optimize Assessment and Clinical Outcome
    Preskorn, Sheldon H.
    JOURNAL OF PSYCHIATRIC PRACTICE, 2016, 22 (06) : 463 - 466
  • [7] Prevalence and clinical correlates of benzodiazepine use in the patients with major depressive disorder
    Wang, Chongze
    Wang, Xiaoxiao
    Wang, Jinde
    Li, Xin
    Lu, Daofeng
    Guo, Fang
    Yao, Yuan
    Zhu, Jiayu
    Shen, Chengjia
    Xie, Qingfang
    Mao, Haiying
    Zhang, Peiyun
    Yang, Xiaolong
    Wu, Haisu
    Lv, Qinyu
    Yi, Zhenghui
    JOURNAL OF AFFECTIVE DISORDERS, 2024, 363 : 619 - 625
  • [8] New agents and perspectives in the pharmacological treatment of major depressive disorder
    Sanches, Marsal
    Quevedo, Joao
    Soares, Jair C.
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2021, 106
  • [9] Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
    Singh, Mandeep
    Schwartz, Thomas L.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2012, 8 : 123 - 130
  • [10] Clinical impact of duloxetine treatment on sleep in patients with major depressive disorder
    Brecht, Stephan
    Kajdasz, Daniel
    Ball, Susan
    Thase, Michael E.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2008, 23 (06) : 317 - 324